Quantcast

Tazemetostat


#1

Epizyme just announced that it intends to initiate a phase 1 trial of EZH2 inhibitor tazemetostat for synovial sarcoma:

http://www.epizyme.com/wp-content/uploads/2015/08/EPZM_News_2015_8_6_General_Releases.pdf

It looks like the clinical trial will be in Europe and Australia:

https://clinicaltrials.gov/ct2/show/NCT01897571

Apparently EZH2 high expression is associated with poor prognosis in synovial sarcoma:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494513/

The trial may be particularly interesting for patients who have the most aggressive form of the disease...


Clinical trials for genomic
#2

A phase 2 trial for tazemetostat is coming:

https://clinicaltrials.gov/ct2/show/NCT02601950


#3

Here are the information about the phase 1 trial:

https://clinicaltrials.gov/ct2/show/NCT02601937


#4

I enrolled.. start date 29 of february..


#5

That's great news! I hope it works!

Kaiowas said:

I enrolled.. start date 29 of february..


#6

An in-vitro and animal study of EZH2 inhibition in synovial sarcoma:


#7

Epizyme finished enrolling all synovial sarcoma patients in its phase 2 trial of Tazemetostat but decided not to investigate further this drug as a monotherapy due to disappointing results:
http://amda-1rbic2.client.shareholder.com/releasedetail.cfm?ReleaseID=1001058


#8

The results of Tazemetostat phase 2 trial will be presented at ASCO in June:
http://abstracts.asco.org/199/AbstView_199_186898.html
Best response was stable disease longer than 16 weeks observed in 5 patients.